Valuation: BioNTech SE

Market Cap 20.39B 23.48B 18.94B 17.47B 32.9B 2,242B 33.5B 224B 87.79B 1,113B 88.18B 86.25B 3,744B P/E 2026 *
-18.3x
P/E 2027 * -17.7x
Enterprise Value 9.54B 10.99B 8.86B 8.17B 15.4B 1,049B 15.68B 105B 41.09B 521B 41.27B 40.36B 1,752B EV / Sales 2026 *
4.4x
EV / Sales 2027 * 4.98x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-0.11%
1 week+0.86%
Current month-0.21%
1 month-0.21%
3 months-10.25%
6 months-18.37%
Current year-2.47%
1 week 88.5
Extreme 88.5
94.38
1 month 88.35
Extreme 88.35
98.81
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Director

1,927 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-0.11%+0.86%-15.63%-13.56% 23.48B
-0.81%-0.33%+27.15%+81.12% 55.23B
-3.74%-6.32%+42.70%+64.45% 53.75B
-1.58%-5.51%-3.51%+375.36% 22B
+2.33%-1.07%+20.12%-12.29% 19.78B
-1.23%-3.15%+26.00%-31.88% 17.44B
+1.37%-5.14%+17.21%+545.40% 14.66B
+1.16%+0.58%+51.87%+181.96% 14.07B
-5.09%-10.87%+153.11%+272.20% 13.02B
-9.83%-9.25%+70.11%+139.94% 11.37B
Average -1.75%-1.54%+38.91%+160.27% 24.48B
Weighted average by Cap. -1.63%-0.49%+32.57%+125.71%

Financials

2026 *2027 *
Net sales 2.17B 2.5B 2.01B 1.86B 3.5B 238B 3.56B 23.83B 9.33B 118B 9.37B 9.17B 398B 2.23B 2.57B 2.07B 1.91B 3.6B 245B 3.66B 24.52B 9.6B 122B 9.64B 9.43B 410B
Net income -1.04B -1.2B -970M -894M -1.68B -115B -1.72B -11.48B -4.5B -57.01B -4.51B -4.42B -192B -1.16B -1.34B -1.08B -997M -1.88B -128B -1.91B -12.8B -5.01B -63.57B -5.04B -4.92B -214B
Net Debt -10.85B -12.49B -10.08B -9.29B -17.5B -1,193B -17.82B -119B -46.7B -592B -46.91B -45.88B -1,992B -9.28B -10.69B -8.62B -7.95B -14.97B -1,020B -15.24B -102B -39.95B -507B -40.13B -39.25B -1,704B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
30/07/26 USD 92.85 -0.11% 1,381,269
29/07/26 USD 92.95 +0.54% 740,136
28/07/26 USD 92.45 +1.49% 679,283
27/07/26 USD 91.09 +1.97% 687,342
24/07/26 USD 89.33 -2.97% 886,104
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
80.65EUR
Average target price
107.04EUR
Spread / Average Target
+32.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock